Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) accounts for over 80% of liver cancer cases and is highly malignant, recurrent, drug-resistant, and often diagnosed in the advanced stage. It is clear that early diagnosis and a better understanding of molecular mechanisms contributing to HCC progression is clinically urgent. Metabolic alterations clearly characterize HCC tumors. Numerous clinical parameters currently used to assess liver functions reflect changes in both enzyme activity and metabolites. Indeed, differences in glucose and acetate utilization are used as a valid clinical tool for stratifying patients with HCC. Moreover, increased serum lactate can distinguish HCC from normal subjects, and serum lactate dehydrogenase is used as a prognostic indicator for HCC patients under therapy. Currently, the emerging field of metabolomics that allows metabolite analysis in biological fluids is a powerful method for discovering new biomarkers. Several metabolic targets have been identified by metabolomics approaches, and these could be used as biomarkers in HCC. Moreover, the integration of different omics approaches could provide useful information on the metabolic pathways at the systems level. In this review, we provided an overview of the metabolic characteristics of HCC considering also the reciprocal influences between the metabolism of cancer cells and their microenvironment. Moreover, we also highlighted the interaction between hepatic metabolite production and their serum revelations through metabolomics researches.

Original languageEnglish
Article number7512159
JournalOxidative Medicine and Cellular Longevity
Volume2018
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Metabolites
Metabolism
Hepatocellular Carcinoma
Biomarkers
Liver
Metabolomics
Enzyme activity
L-Lactate Dehydrogenase
Tumors
Lactic Acid
Acetates
Therapeutics
Cells
Glucose
Fluids
Serum
Cellular Microenvironment
Pharmaceutical Preparations
Liver Neoplasms
Metabolic Networks and Pathways

ASJC Scopus subject areas

  • Biochemistry
  • Ageing
  • Cell Biology

Cite this

@article{1bc8ac4c6c9d4e95b0408136ebd22f5f,
title = "Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities",
abstract = "Hepatocellular carcinoma (HCC) accounts for over 80{\%} of liver cancer cases and is highly malignant, recurrent, drug-resistant, and often diagnosed in the advanced stage. It is clear that early diagnosis and a better understanding of molecular mechanisms contributing to HCC progression is clinically urgent. Metabolic alterations clearly characterize HCC tumors. Numerous clinical parameters currently used to assess liver functions reflect changes in both enzyme activity and metabolites. Indeed, differences in glucose and acetate utilization are used as a valid clinical tool for stratifying patients with HCC. Moreover, increased serum lactate can distinguish HCC from normal subjects, and serum lactate dehydrogenase is used as a prognostic indicator for HCC patients under therapy. Currently, the emerging field of metabolomics that allows metabolite analysis in biological fluids is a powerful method for discovering new biomarkers. Several metabolic targets have been identified by metabolomics approaches, and these could be used as biomarkers in HCC. Moreover, the integration of different omics approaches could provide useful information on the metabolic pathways at the systems level. In this review, we provided an overview of the metabolic characteristics of HCC considering also the reciprocal influences between the metabolism of cancer cells and their microenvironment. Moreover, we also highlighted the interaction between hepatic metabolite production and their serum revelations through metabolomics researches.",
author = "{De Matteis}, Serena and Andrea Ragusa and Giorgia Marisi and {De Domenico}, Stefania and {Casadei Gardini}, Andrea and Massimiliano Bonaf{\`e} and Giudetti, {Anna Maria}",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/7512159",
language = "English",
volume = "2018",
journal = "Oxidative Medicine and Cellular Longevity",
issn = "1942-0900",
publisher = "Hindawi Limited",

}

TY - JOUR

T1 - Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities

AU - De Matteis, Serena

AU - Ragusa, Andrea

AU - Marisi, Giorgia

AU - De Domenico, Stefania

AU - Casadei Gardini, Andrea

AU - Bonafè, Massimiliano

AU - Giudetti, Anna Maria

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Hepatocellular carcinoma (HCC) accounts for over 80% of liver cancer cases and is highly malignant, recurrent, drug-resistant, and often diagnosed in the advanced stage. It is clear that early diagnosis and a better understanding of molecular mechanisms contributing to HCC progression is clinically urgent. Metabolic alterations clearly characterize HCC tumors. Numerous clinical parameters currently used to assess liver functions reflect changes in both enzyme activity and metabolites. Indeed, differences in glucose and acetate utilization are used as a valid clinical tool for stratifying patients with HCC. Moreover, increased serum lactate can distinguish HCC from normal subjects, and serum lactate dehydrogenase is used as a prognostic indicator for HCC patients under therapy. Currently, the emerging field of metabolomics that allows metabolite analysis in biological fluids is a powerful method for discovering new biomarkers. Several metabolic targets have been identified by metabolomics approaches, and these could be used as biomarkers in HCC. Moreover, the integration of different omics approaches could provide useful information on the metabolic pathways at the systems level. In this review, we provided an overview of the metabolic characteristics of HCC considering also the reciprocal influences between the metabolism of cancer cells and their microenvironment. Moreover, we also highlighted the interaction between hepatic metabolite production and their serum revelations through metabolomics researches.

AB - Hepatocellular carcinoma (HCC) accounts for over 80% of liver cancer cases and is highly malignant, recurrent, drug-resistant, and often diagnosed in the advanced stage. It is clear that early diagnosis and a better understanding of molecular mechanisms contributing to HCC progression is clinically urgent. Metabolic alterations clearly characterize HCC tumors. Numerous clinical parameters currently used to assess liver functions reflect changes in both enzyme activity and metabolites. Indeed, differences in glucose and acetate utilization are used as a valid clinical tool for stratifying patients with HCC. Moreover, increased serum lactate can distinguish HCC from normal subjects, and serum lactate dehydrogenase is used as a prognostic indicator for HCC patients under therapy. Currently, the emerging field of metabolomics that allows metabolite analysis in biological fluids is a powerful method for discovering new biomarkers. Several metabolic targets have been identified by metabolomics approaches, and these could be used as biomarkers in HCC. Moreover, the integration of different omics approaches could provide useful information on the metabolic pathways at the systems level. In this review, we provided an overview of the metabolic characteristics of HCC considering also the reciprocal influences between the metabolism of cancer cells and their microenvironment. Moreover, we also highlighted the interaction between hepatic metabolite production and their serum revelations through metabolomics researches.

UR - http://www.scopus.com/inward/record.url?scp=85057049062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057049062&partnerID=8YFLogxK

U2 - 10.1155/2018/7512159

DO - 10.1155/2018/7512159

M3 - Review article

C2 - 30524660

AN - SCOPUS:85057049062

VL - 2018

JO - Oxidative Medicine and Cellular Longevity

JF - Oxidative Medicine and Cellular Longevity

SN - 1942-0900

M1 - 7512159

ER -